This study is testing a new medicine, DB-1303/BNT323, for people with tough-to-treat cancers (called HER2-positive tumors). HER2 is a protein that can make cancer grow. The study is in two parts: the first part finds a safe dose, and the second part checks how well it works. The study involves taking this medicine multiple times and is happening at many places. You might join if your cancer can't be removed by surgery, keeps coming back, or has spread to other parts of your body.
- Length: The study has two phases, and you may need to visit the study center multiple times.
- Risks: There are risks like side effects from the new medicine.
- Eligibility: You need to have a specific type of cancer and meet health criteria.
Note: Medical terms explained - Metastatic: cancer has spread; Refractory: doesn't respond to treatment; ECOG: a scale to measure daily living ability; LVEF: heart's pumping ability; CHF: heart failure.